RESUMO
OBJECTIVE: The purpose of this study was to evaluate the long-term survival rate of Methotrexate (MTX) in the peripheral joint involvement of psoriatic arthritis (PsA) in a setting of everyday clinical practice. METHODS: This was an observational restrospective study performed using the data from a dermatological-rheumatological PsA clinic. All of the patients evaluated at this clinic from March 1997 to December 2007 who were started on MTX alone, had a three-year follow-up time or had discontinued the therapy were included into the survey. RESULTS: Of the 174 evaluable patients, 104 (59.8%) were still taking MTX after three years of treatment. The reasons of therapy discontinuation in the remaining 70 (40.2%) patients were: 34 (19.5%) lost-to-follow-up, 18 (10.3%) adverse events, 14 (8%) inefficacies, and 4 (2.3%) deaths (none related to the therapy). MTX was effective in controlling joint inflammation but not in preventing their deterioration. Overall, adverse events were recorded in 43 patients (36.4% of the 114 patients with a three-year follow-up). No serious side effect occurred in the study population. CONCLUSIONS: The results of this study showed that, in a setting of clinical pratice, MTX had a good three-year performance in patients with peripheral PsA. Almost 60% of them were still taking this drug at the end of the study period and the toxicity was more than acceptable. In our opinion, MTX might be considered the non-biological DMARD of choice for the treatment of this condition. However it should be used earlier and at higher doses.
Assuntos
Antirreumáticos/uso terapêutico , Artrite Psoriásica/tratamento farmacológico , Metotrexato/uso terapêutico , Adulto , Antirreumáticos/efeitos adversos , Feminino , Seguimentos , Humanos , Masculino , Metotrexato/efeitos adversos , Pessoa de Meia-Idade , Estudos Retrospectivos , Análise de Sobrevida , Fatores de Tempo , Resultado do TratamentoRESUMO
OBJECTIVE: To determine whether patients with early rheumatoid arthritis (RA) treated with cyclosporin A (CsA) and methotrexate (MTX) in combination for 12 months show a lower rate of radiographic deterioration than those treated with MTX alone. METHODS: In this controlled and randomized single-blind trial, 61 consecutive patients with untreated RA of less than 2 yr duration were treated with either CsA + MTX combination therapy (n = 30) or MTX alone (n = 31). The primary end-point was radiographic progression after 12 months, measured using the damage score (DS) of the Sharp and van der Heijde method. RESULTS: Although there was a significant difference between the mean baseline and 12-month DS in both treatment groups (MTX/CsA, 1.93 +/- 0.90; MTX, 7.47 +/- 2.03), it was significantly less in the combination arm (P = 0.018). Of the 30 evaluable CsA + MTX patients, 16 (53%) were ACR20 responders, 15 (50%) ACR50 and 14 (47%) ACR70; the corresponding figures in the MTX arm were 19 (61%), 13 (44%) and 6 (19%). Toxicity was acceptable in both groups. CONCLUSIONS: In patients with early RA, CsA + MTX combination therapy led to a significantly lower rate of 12-month radiographic progression, was effective on inflammatory articular symptoms, and was well tolerated.
Assuntos
Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Ciclosporina/uso terapêutico , Imunossupressores/uso terapêutico , Metotrexato/uso terapêutico , Adulto , Antirreumáticos/efeitos adversos , Artrite Reumatoide/diagnóstico por imagem , Ciclosporina/efeitos adversos , Progressão da Doença , Quimioterapia Combinada , Feminino , Humanos , Imunossupressores/efeitos adversos , Masculino , Metotrexato/efeitos adversos , Pessoa de Meia-Idade , Radiografia , Método Simples-Cego , Resultado do TratamentoAssuntos
Antirreumáticos/efeitos adversos , Artrite Reumatoide/tratamento farmacológico , Pancitopenia/induzido quimicamente , Idoso , Anti-Inflamatórios/uso terapêutico , Anticorpos Monoclonais/efeitos adversos , Quimioterapia Combinada , Humanos , Infliximab , Isoxazóis/efeitos adversos , Leflunomida , Masculino , Metotrexato/uso terapêutico , EsteroidesRESUMO
OBJECTIVE: To determine the safety and efficacy of 3 clinically relevant vaccines in patients with systemic lupus erythematosus (SLE). METHODS: We studied 73 consecutive SLE patients immunized with pneumococcal, tetanus toxoid (TT), and Haemophilus influenzae type B (HIB) vaccines. Patients were evaluated preimmunization and 12 weeks postimmunization for disease activity and immunization side effects. RESULTS: Eighty-four percent of the SLE patients developed a 4-fold titer increase in response to at least 1 vaccine, with 51% developing a 2-fold titer increase with all 3 vaccines. The majority of SLE patients developed protective levels of antibody to TT (90%) and HIB (88%). Although protective antibody levels could not be determined for pneumococcus, almost half of the patients (47%) developed a 4-fold antibody response. There was a trend toward a lower antibody response in patients with active disease treated with immunosuppressive therapy. Overall lupus disease activity was unaffected by immunization. CONCLUSION: Immunization is safe in SLE patients, with the overwhelming majority developing protective antibody levels. Therefore, SLE patients should receive immunizations according to the recommendations of the Centers for Disease Control and Prevention and the Immunization Practices Advisory Committee.
Assuntos
Epitopos/imunologia , Imunização , Lúpus Eritematoso Sistêmico/imunologia , Adolescente , Adulto , Idoso , Formação de Anticorpos/efeitos dos fármacos , Azatioprina/farmacologia , Vacinas Bacterianas/administração & dosagem , Ciclofosfamida/farmacologia , Vacinas Anti-Haemophilus/administração & dosagem , Humanos , Imunização/efeitos adversos , Pessoa de Meia-Idade , Prednisona/farmacologia , Streptococcus pneumoniae/imunologia , Toxoide Tetânico/administração & dosagemRESUMO
In this study we aimed at evaluating the modifications in the pharmacokinetic profile of cyclosporin A (CyA) after conversion from standard formulation (CyA-ST) to a new formulation (CyA-NF, Sandimmun Neoral) in patients with rheumatoid arthritis (RA). It was an open, crossover study that involved 15 RA patients who were on stabilized treatment with CyA-ST. The patient continued receiving CyA-ST (mean dose of 3.0 +/- 0.7 mg/kg per day) for 3 weeks and then converted 1:1 to CyA-NF for a further 3 weeks. CyA pharmacokinetics were established on day 1 (CyA-ST evaluation) and +21 (CyA-NF evaluation). The results showed that the bioavailability of CyA-NF was greater than that of CyA-ST (AUC tau, bss: 3335 +/- 1300 vs 2667 +/- 1155 ng.h/ml, P = 0.0073; AUC tau, bss ratio 1.26 +/- 0.40 vs 1.0 as reference, P < 0.05), with higher and earlier peak blood concentrations (Cmax: 677 +/- 256 vs 475 +/- 213 ng/ml, P = 0.0329; tmax: 1.5 +/- 0.7 vs 2.6 +/- 1.6 h, P = 0.0720). The pharmacokinetic profile of CyA-NF showed greater between-patient reproducibility (lower CV% for all of the considered parameters). In conclusion, when using CyA-NF instead of CyA-ST, greater and more constant exposure to CyA should be expected.
Assuntos
Artrite Reumatoide/tratamento farmacológico , Ciclosporina/farmacocinética , Imunossupressores/farmacocinética , Adolescente , Adulto , Disponibilidade Biológica , Pressão Sanguínea/efeitos dos fármacos , Química Farmacêutica , Creatinina/sangue , Estudos Cross-Over , Ciclosporina/administração & dosagem , Ciclosporina/sangue , Interpretação Estatística de Dados , Diástole , Relação Dose-Resposta a Droga , Feminino , Gastroenteropatias/induzido quimicamente , Hiperplasia Gengival/induzido quimicamente , Cefaleia/induzido quimicamente , Hemoglobinas/efeitos dos fármacos , Hemoglobinas/metabolismo , Humanos , Imunossupressores/administração & dosagem , Imunossupressores/efeitos adversos , Articulações/efeitos dos fármacos , Articulações/patologia , Testes de Função Renal , Testes de Função Hepática , Masculino , Pessoa de Meia-Idade , Sístole , Fatores de Tempo , Tremor/induzido quimicamente , Ácido Úrico/metabolismoRESUMO
OBJECTIVE: To evaluate the frequency of arthropathy and osteoporosis in genetic hemochromatosis (GH) and to quantify potential risk factors for these 2 conditions. METHODS: Radiographic evidence of arthropathy was systematically sought in plain radiographs of 32 patients (28 men) with histologically proven GH (17 with hepatic cirrhosis). Bone mineral density was measured by x-ray absorptiometry of L2-L4 and osteoporosis was defined as a T score > or = 2.5 standard deviation below the mean. Potential risk factors investigated were age, body mass index, cirrhosis, alcohol abuse, hepatitis B and C infections, HLA phenotype, serum free testosterone levels, and the amount of iron removed by phlebotomy to reach depletion. The independent role of risk factors for the presence of osteoporosis was tested by multiple logistic regression analysis. RESULTS: Radiologic signs of arthropathy were observed in 81.3% of cases. Patients with arthropathy were older than patients without (p < 0.001), but did not differ in the frequency of cirrhosis, amount of iron removed, and HLA typing. Osteoporosis was observed in 9 patients and was positively associated with the amount of iron removed and cirrhosis. However, in multivariate analysis, cirrhosis was not independently associated with osteoporosis, but patients with higher iron removed had a greater probability to have osteoporosis [odds ratio (OR) = 3.23 for any increase of 5 g, 95% confidence interval (CI): 1.09-9.58], whereas the presence of HLA-A3 was associated with a reduction of risk (OR 0.013, 95% CI: 0.0015-1.13). CONCLUSION: These findings indicate the high prevalence of osteoarticular involvement in Italian patients with GH. Neither cirrhosis nor the amount of iron removed was associated with arthropathy. In contrast, in univariate analysis the risk of osteoporosis was significantly increased by liver cirrhosis. With multivariate analysis we found that osteoporosis was highly influenced by the degree of iron overload, playing an independent role in accelerating bone loss in patients with GH.
Assuntos
Hemocromatose/genética , Sobrecarga de Ferro/fisiopatologia , Cirrose Hepática/fisiopatologia , Osteoartrite/epidemiologia , Osteoporose/epidemiologia , Adulto , Artrografia , Densidade Óssea , Feminino , Hemocromatose/fisiopatologia , Humanos , Itália/epidemiologia , Masculino , Pessoa de Meia-Idade , Osteoartrite/diagnóstico por imagem , Osteoartrite/fisiopatologia , Osteoporose/diagnóstico por imagem , Osteoporose/fisiopatologia , Prevalência , Fatores de RiscoRESUMO
OBJECTIVE: To determine whether cyclosporin A (CyA) is a useful option in the treatment of adult onset Still's disease (ASD). METHODS: Low dose CyA was given to 6 patients with chronic or relapsing ASD who had not been prescribed any other second line agents during the previous 6 mo. RESULTS: The disease completely remitted in 4 patients and improved markedly in the remaining 2. The corticosteroid requirement was substantially reduced in all cases. Tolerability was rated good or very good by all patients but one, who reported good tolerance to CyA only in a new formulation. CONCLUSION: CyA may be included among the second line agents used in the treatment of refractory ASD.
Assuntos
Antirreumáticos/uso terapêutico , Ciclosporina/uso terapêutico , Doença de Still de Início Tardio/tratamento farmacológico , Administração Oral , Adolescente , Adulto , Antirreumáticos/efeitos adversos , Ciclosporina/efeitos adversos , Feminino , Humanos , Masculino , Doença de Still de Início Tardio/fisiopatologia , Resultado do TratamentoAssuntos
Hepacivirus/imunologia , Anticorpos Anti-Hepatite/sangue , Lúpus Eritematoso Sistêmico/imunologia , Adulto , Idoso , Feminino , Hepatite C/complicações , Hepatite C/imunologia , Anticorpos Anti-Hepatite C , Humanos , Lúpus Eritematoso Sistêmico/complicações , Lúpus Eritematoso Sistêmico/virologia , Pessoa de Meia-IdadeRESUMO
This study was aimed to evaluate the usefulness of rifamycin SV as an agent for local treatment of rheumatoid synovitis. Rifamycin SV was compared with triamcinolone acetonide in a randomized controlled trial on 87 patients with rheumatoid arthritis and with persistent knee synovitis. The treatment with rifamycin consisted of several weekly intra-articular injections, whereas triamcinolone was given as a single intra-articular injection. At the end of the therapy, 27 (61.4%) of the 44 rifamycin patients and 39 (91%) of the 43 steroid patients responded well to the treatment, and this difference was significant (p < 0.01). Rifamycin SV was responsible for unpleasant local side effects in all cases. In both groups, after 1 year of follow-up the synovitis had relapsed in about 42% of cases. We conclude that rifamycin SV is less useful than triamcinolone acetonide in the local treatment of rheumatoid synovitis.
Assuntos
Artrite Reumatoide/tratamento farmacológico , Rifamicinas/uso terapêutico , Sinovite/tratamento farmacológico , Triancinolona/uso terapêutico , Adulto , Feminino , Humanos , Injeções Intra-Articulares , Masculino , Rifamicinas/efeitos adversos , Triancinolona/efeitos adversosRESUMO
Iron overload is frequently present in patients with thalassemia intermedia, and it becomes evident mainly after the second and third decades of life. The degree of the iron load is heterogeneous ranging from mild to severe. In this study we evaluated the iron status of 38 adult patients with thalassemia intermedia and we looked for factors possibly related to the observed heterogeneity of the iron status. The levels of transferrin saturation (TS), serum ferritin (SF) and desferrioxamine-induced urinary iron excretion (DFU) were spread in a wide range from normal to markedly increased. These indices did not correlate with other parameters such as age, hemoglobin levels and entity of the erythropoietic status. A significant difference in the degree of iron overload was observed between patients who underwent splenectomy and non-splenectomized patients. TS, SF and DFU were significantly higher in splenectomized than in non- splenectomized patients, indicating that the spleen could have a role in the regulation of iron metabolism in these patients.